Ozempic vs Mounjaro
Editorial comparison of Ozempic (semaglutide) and Mounjaro (tirzepatide). Same drug class context, trial-anchored data, no marketing claims.
Side-by-side
| Dimension | Ozempic | Mounjaro |
|---|---|---|
| Generic name | semaglutide | tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approved | 2017 | 2022 |
| Mechanism | Same mechanism as Wegovy — GLP-1 receptor agonist. | Same as Zepbound — dual GLP-1/GIP receptor agonist. Strong glycemic effect plus weight loss. |
| Dosing | 0.25mg weekly for 4 weeks, then 0.5mg, then 1mg, max 2mg. Lower max dose than Wegovy (2.4mg). | Titrated 2.5mg → 15mg weekly over months, same schedule as Zepbound. |
| Cost | List price ~$900-1,000/month. | Similar to Zepbound — list ~$1,000/month, LillyDirect Self-Pay $399-549/month. |
| Pivotal trial result | 1.4–1.8% HbA1c reduction across SUSTAIN trials (1.0 mg dose) | 2.0–2.3% HbA1c reduction across SURPASS trials (15 mg dose) |
Efficacy in the trials
1.4–1.8% HbA1c reduction across SUSTAIN trials (1.0 mg dose)
SUSTAIN-6 (NCT01720446) — cardiovascular outcomes · vs placebo, 26% reduction in major adverse cardiovascular events · n=3,297
2.0–2.3% HbA1c reduction across SURPASS trials (15 mg dose)
SURPASS-2 (NCT03987919) — vs semaglutide · Tirzepatide 15 mg achieved 2.30% HbA1c reduction vs 1.86% for semaglutide 1 mg · n=1,879
Trial averages describe study populations, not individuals. Response varies with the dose tolerated, adherence, and personal physiology; the two drugs were not necessarily tested head-to-head in the same trial.
The details
Dosing & cadence
Cost & access
Side effects
Which should you choose?
If maximizing average trial weight loss is the priority, Mounjaro posted the higher pivotal-trial figure; Ozempic still produced clinically meaningful loss and some people tolerate it better. On cost and access, compare each drug's manufacturer direct-pay and insurance path — that often matters more month-to-month than the efficacy gap. Both carry class safety considerations (see each drug's boxed-warning and contraindications); a personal or family history of medullary thyroid carcinoma or MEN2 rules out the GLP-1 class. Bring this comparison to a prescriber, who will match the drug to your history and titrate the dose.
This is editorial framing, not a prescription. The right choice depends on your medical history, insurance, and a clinician's evaluation.
Full Ozempic review →
FDA-approved semaglutide for type 2 diabetes. Widely used off-label for weight loss.
Full Mounjaro review →
FDA-approved tirzepatide for type 2 diabetes. Off-label for weight loss is common.
Deciding at the molecule level? Semaglutide vs Tirzepatide compares the two drug families behind every major GLP-1 brand.
Frequently asked
Is Ozempic or Mounjaro more effective?+
In their pivotal trials, Ozempic reported 1.4–1.8% HbA1c reduction across SUSTAIN trials (1.0 mg dose), while Mounjaro reported 2.0–2.3% HbA1c reduction across SURPASS trials (15 mg dose). Head-to-head results vary by patient profile, dose tolerated, and adherence — these trial numbers describe averages, not what every individual experiences.
How do Ozempic and Mounjaro compare on cost?+
Ozempic: List price ~$900-1,000/month. Diabetes coverage is generally better than weight-loss coverage — many insurance plans cover Ozempic with a T2D diagnosis at standard copay. Mounjaro: Similar to Zepbound — list ~$1,000/month, LillyDirect Self-Pay $399-549/month. Real out-of-pocket depends on insurance formulary tier, manufacturer savings programs, and whether a direct-pay channel is available.
Can I switch from Ozempic to Mounjaro?+
Switching between brand-name treatments in the same drug class is common, but the conversion is not always 1:1. Discuss the switch with your prescriber — they'll usually re-titrate dosing rather than substitute equivalent strengths directly.
Are Ozempic and Mounjaro the same drug?+
No. Ozempic (semaglutide) and Mounjaro (tirzepatide) are distinct medications from Novo Nordisk and Eli Lilly respectively. They may share a drug class or mechanism but differ in active ingredient, dosing, and approved use.